Format
Items per page
Sort by

Send to:

Choose Destination

Results: 7

Related Articles by Review for PubMed (Select 19837979)

1.

Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma.

Chen L, Wang S, Zhou Y, Wu X, Entin I, Epstein J, Yaccoby S, Xiong W, Barlogie B, Shaughnessy JD Jr, Zhan F.

Blood. 2010 Jan 7;115(1):61-70. doi: 10.1182/blood-2009-03-210526. Epub 2009 Oct 16.

2.

The effects of bortezomib on bone disease in patients with multiple myeloma.

Mohty M, Malard F, Mohty B, Savani B, Moreau P, Terpos E.

Cancer. 2014 Mar 1;120(5):618-23. doi: 10.1002/cncr.28481. Epub 2013 Nov 18. Review.

3.

Growth factors and antiapoptotic signaling pathways in multiple myeloma.

van de Donk NW, Lokhorst HM, Bloem AC.

Leukemia. 2005 Dec;19(12):2177-85. Review.

PMID:
16239913
4.

The role of bone morphogenetic proteins in myeloma cell survival.

Holien T, Sundan A.

Cytokine Growth Factor Rev. 2014 Jun;25(3):343-50. doi: 10.1016/j.cytogfr.2014.04.009. Epub 2014 May 9. Review.

PMID:
24853340
5.

Targeting the IGF-1R signaling and mechanisms for epigenetic gene silencing in human multiple myeloma.

Jernberg-Wiklund H, Nilsson K.

Ups J Med Sci. 2012 May;117(2):166-77. doi: 10.3109/03009734.2012.659293. Epub 2012 Feb 21. Review.

6.

Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects.

Reagan MR, Ghobrial IM.

Clin Cancer Res. 2012 Jan 15;18(2):342-9. doi: 10.1158/1078-0432.CCR-11-2212. Epub 2011 Nov 7. Review.

7.

Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Asimakopoulos F, Kim J, Denu RA, Hope C, Jensen JL, Ollar SJ, Hebron E, Flanagan C, Callander N, Hematti P.

Leuk Lymphoma. 2013 Oct;54(10):2112-21. doi: 10.3109/10428194.2013.778409. Epub 2013 Apr 11. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk